The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Table 2 Base case clinical results: fractures avoided per 1,000 patients

Cohort Evaluated	Hip Fractures	Vertebral Fractures	Wrist Fractures
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment	95	221	32
Teriparatide vs. bisphosphonate	66	166	27
incident vertebral fracture
Teriparatide vs. No Treatment	73	145	27
Teriparatide vs. bisphosphonate	51	108	22
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment	93	304	36
Teriparatide vs. bisphosphonate	63	227	30
incident vertebral fracture
Teriparatide vs. No Treatment	85	248	34
Teriparatide vs. bisphosphonate	57	184	28

ISSN: 1471-2474